Compare KLAR & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLAR | ARWR |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 9.6B |
| IPO Year | 2025 | 1993 |
| Metric | KLAR | ARWR |
|---|---|---|
| Price | $31.07 | $65.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $46.64 | ★ $63.70 |
| AVG Volume (30 Days) | 2.2M | ★ 2.5M |
| Earning Date | 02-25-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,209,000,000.00 | $829,448,000.00 |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | $29.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 17.82 | ★ 23258.15 |
| 52 Week Low | $27.90 | $9.57 |
| 52 Week High | $57.20 | $76.76 |
| Indicator | KLAR | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.91 |
| Support Level | N/A | $60.62 |
| Resistance Level | N/A | $76.76 |
| Average True Range (ATR) | 0.00 | 3.50 |
| MACD | 0.00 | -1.13 |
| Stochastic Oscillator | 0.00 | 37.24 |
Klarna is the largest pure-play in the buy now, pay later space. The company operates a two-sided network with a payment method at its core, but it is ultimately a lender. Merchants sign up with Klarna to increase turnover in their stores. Primarily, Klarna can provide merchants with higher conversion rates and average order values relative to other payment methods. Some merchants enter a symbiotic relationship with Klarna, advertising its brand on the product page to drive conversion and to benefit from Klarna's brand value in the merchant's sales funnel. Customers use Klarna for its ease of use, quick access to credit, zero-interest financing, and lower reminder fees.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.